Literature DB >> 3607725

Prognostic significance of plasma cell morphology in multiple myeloma.

A Carter, I Hocherman, S Linn, Y Cohen, I Tatarsky.   

Abstract

The effect of bone marrow plasma cell morphology at diagnosis on survival time was evaluated in 139 patients with multiple myeloma. According to the morphological classification scheme the patients were categorized as mature (30 patients), immature (76 patients) or plasmablastic (33 patients). The plasmablastic group had an estimated median survival (Kaplan-Meier method) of 10.9 months, compared with 32.2 months for immature and 60 months for mature types (P = 0.0000). The prognostic value of a morphologic classification in multiple myeloma was further demonstrated by means of a multivariate linear regression analysis of survival data. Expected survival was calculated using clinical features and morphologic subtypes. The estimated survival time for plasmablastic myeloma was shorter by 51.4 months and for immature myeloma patients by 35 months, compared with mature myeloma patients with similar clinical characteristics. Plasma cell morphology at diagnosis is an important predictor of survival duration in patients with multiple myeloma.

Entities:  

Mesh:

Year:  1987        PMID: 3607725     DOI: 10.1002/1097-0142(19870901)60:5<1060::aid-cncr2820600522>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Authors:  R Leo; M Boeker; D Peest; R Hein; R Bartl; J E Gessner; J Selbach; G Wacker; H Deicher
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

2.  Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies.

Authors:  A Pich; L Chiusa; F Marmont; N Cappello; R Navone
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; A Castello; A Coci; U Magrini; E Ascari
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

4.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

5.  Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Miguel-Garcia; E Matutes; F Tarin; J Garcia-Talavera; A Miguel-Sosa; F Carbonell; D Catovsky
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

6.  A prognostic index for multiple myeloma.

Authors:  G Grignani; P G Gobbi; R Formisano; C Pieresca; G Ucci; S Brugnatelli; A Riccardi; E Ascari
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

7.  The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple Myeloma.

Authors:  Szymon Zmorzyński; Sylwia Popek-Marciniec; Aneta Szudy-Szczyrek; Magdalena Wojcierowska-Litwin; Iwona Korszeń-Pilecka; Sylwia Chocholska; Wojciech Styk; Marek Hus; Agata A Filip
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

8.  Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma.

Authors:  Hyoeun Shim; Joo Hee Ha; Hyewon Lee; Ji Yeon Sohn; Hyun Ju Kim; Hyeon-Seok Eom; Sun-Young Kong
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

9.  Bimodal immunoglobulin A gammopathy in a cat with feline myeloma-related disorders.

Authors:  Masaya Igase; Takako Shimokawa Miyama; Satoshi Kambayashi; Yumiko Shimoyama; Hiroko Hiraoka; Yumi Hirata; Miki Iwata; Kenji Baba; Takuya Mizuno; Masaru Okuda
Journal:  J Vet Med Sci       Date:  2015-12-04       Impact factor: 1.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.